Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GILD
  • CUSIP: 37555810
  • Web: www.gilead.com
Capitalization:
  • Market Cap: $96.94615 billion
  • Outstanding Shares: 1,306,728,000
Average Prices:
  • 50 Day Moving Avg: $69.64
  • 200 Day Moving Avg: $68.63
  • 52 Week Range: $63.76 - $82.10
P/E:
  • Trailing P/E Ratio: 7.92
  • Foreward P/E Ratio: 10.44
  • P/E Growth: -1.07
Sales & Book Value:
  • Annual Revenue: $29.1 billion
  • Price / Sales: 3.37
  • Book Value: $15.64 per share
  • Price / Book: 4.79
Dividend:
  • Annual Dividend: $2.08
  • Dividend Yield: 2.8%
Profitability:
  • EBIDTA: $18.24 billion
  • Net Margins: 43.42%
  • Return on Equity: 76.64%
  • Return on Assets: 25.55%
Debt:
  • Debt-to-Equity Ratio: 1.26%
  • Current Ratio: 2.59%
  • Quick Ratio: 2.41%
Misc:
  • Average Volume: 8.57 million shs.
  • Beta: 1.21
  • Short Ratio: 1.29
 
Frequently Asked Questions for Gilead Sciences (NASDAQ:GILD)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Wednesday, July 26th. Investors of record on Friday, September 15th will be given a dividend of $0.52 per share on Thursday, September 28th. This represents a $2.08 annualized dividend and a dividend yield of 2.77%. The ex-dividend date is Thursday, September 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) released its quarterly earnings results on Wednesday, July, 26th. The company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analysts' expectations of $6.35 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. Gilead Sciences's revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period last year, the firm earned $3.08 EPS. View Gilead Sciences' Earnings History.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?

26 brokers have issued 12 month price targets for Gilead Sciences' stock. Their forecasts range from $65.50 to $95.00. On average, they anticipate Gilead Sciences' share price to reach $80.40 in the next twelve months. View Analyst Ratings for Gilead Sciences.

What are analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • 1. According to Zacks Investment Research, "Gilead’s HIV franchise has been gaining momentum of late. Rapid adoption of TAF-based regimens, representing 42% of total Gilead HIV prescription volume, following the launch of Genvoya and the launches of Odefsey and Descovy in 2016 boosted results. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales.The company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. The company submitted a NDA to the FDA for single tablet regimen for bictegravir. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. In addition, the HCV franchise continues to be under competitive and pricing pressure leading to a decline in Harvoni and Sovaldi sales." (7/18/2017)
  • 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
  • 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
  • 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest during the month of June. As of June 30th, there was short interest totalling 13,658,785 shares, an increase of 15.7% from the June 15th total of 11,804,652 shares. Based on an average daily volume of 13,707,757 shares, the short-interest ratio is currently 1.0 days. Approximately 1.1% of the company's shares are short sold.

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

  • John C. Martin Ph.D., Executive Chairman of the Board
  • John F. Milligan Ph.D., Chief Executive Officer, Director
  • Robin L. Washington, Chief Financial Officer, Executive Vice President
  • Kevin B. Young, Chief Operating Officer
  • Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
  • Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs
  • James R. Meyers, Executive Vice President - Worldwide Commercial Operations
  • John F. Cogan Jr. Ph.D., Lead Independent Director
  • Kelly A. Kramer, Independent Director
  • Kevin E. Lofton, Independent Director

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include APG Asset Management N.V. (0.42%), State Treasurer State of Michigan (0.24%), Swedbank (0.17%), Bessemer Group Inc. (0.14%), Great West Life Assurance Co. Can (0.14%) and Strs Ohio (0.11%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., APG Asset Management N.V., Rothschild Asset Management Inc., NN Investment Partners Holdings N.V., First Quadrant L P CA, Boston Advisors LLC, Parkwood LLC and Meag Munich Ergo Kapitalanlagegesellschaft MBH. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter. View Insider Buying and Selling for Gilead Sciences.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was bought by a variety of institutional investors in the last quarter, including Harbour Capital Advisors LLC, ANTIPODES PARTNERS Ltd, Aperio Group LLC, Foundation Resource Management Inc., Manning & Napier Advisors LLC, Mn Services Vermogensbeheer B.V., US Bancorp DE and Boston Financial Mangement LLC. View Insider Buying and Selling for Gilead Sciences.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of Gilead Sciences stock can currently be purchased for approximately $74.96.


MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  1,514 (Vote Outperform)
Underperform Votes:  496 (Vote Underperform)
Total Votes:  2,010
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 10 Hold Ratings, 16 Buy Ratings
Consensus Rating:Buy (Score: 2.62)
Consensus Price Target: $80.40 (7.25% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Cowen and CompanyReiterated RatingOutperform$90.00LowView Rating Details
7/27/2017Deutsche Bank AGReiterated RatingBuy$79.00 -> $81.00LowView Rating Details
7/27/2017BMO Capital MarketsReiterated RatingOutperform$72.00 -> $82.00LowView Rating Details
7/27/2017Jefferies Group LLCReiterated RatingHold$83.00LowView Rating Details
7/27/2017Maxim GroupReiterated RatingHoldMediumView Rating Details
7/27/2017J P Morgan Chase & CoSet Price TargetOverweight$80.00 -> $85.00MediumView Rating Details
7/26/2017Redburn PartnersInitiated CoverageBuyMediumView Rating Details
7/25/2017Robert W. BairdReiterated RatingOutperform$87.00LowView Rating Details
7/25/2017Leerink SwannReiterated RatingHold$74.00LowView Rating Details
7/11/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
6/16/2017William BlairReiterated RatingOutperformLowView Rating Details
5/15/2017Credit Suisse GroupReiterated RatingOutperform$79.00N/AView Rating Details
5/3/2017GabelliReiterated RatingBuy$85.00MediumView Rating Details
5/3/2017Barclays PLCReiterated RatingOverweight$85.00MediumView Rating Details
5/3/2017Stifel NicolausReiterated RatingBuy$87.00MediumView Rating Details
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
3/13/2017Bank of America CorporationReiterated RatingNeutral$76.00 -> $68.19LowView Rating Details
3/13/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$70.00 -> $68.00LowView Rating Details
3/1/2017MizuhoLower Price TargetBuy$88.00 -> $77.00N/AView Rating Details
2/14/2017Berenberg BankSet Price TargetBuy$112.00 -> $78.00N/AView Rating Details
2/8/2017Royal Bank Of CanadaLower Price Target$75.00N/AView Rating Details
2/8/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/8/2017Citigroup Inc.DowngradeBuy -> Neutral$87.00 -> $76.00N/AView Rating Details
2/8/2017Wells Fargo & CompanyReiterated RatingMarket Perform$79.50 -> $65.50N/AView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
7/29/2016ArgusDowngradeBuy -> Hold$88.00 -> $81.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
5/4/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$120.00 -> $116.00N/AView Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00N/AView Rating Details
9/10/2015Jyske BankUpgradeStrong-Buy$125.00N/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for Gilead Sciences (NASDAQ:GILD)
Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)
Earnings History by Quarter for Gilead Sciences (NASDAQ GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017Q2 2017$2.11$2.56$6.35 billion$7.14 billionViewN/AView Earnings Details
5/2/2017Q1 2017$2.18$2.20$6.66 billion$6.51 billionViewListenView Earnings Details
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
2017 EPS Consensus Estimate: $8.27
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$2.09$2.42$2.23
Q2 20173$2.01$2.29$2.15
Q3 20173$1.88$2.15$1.99
Q4 20173$1.79$2.09$1.91
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Next Dividend:9/28/2017
Annual Dividend:$2.08
Dividend Yield:2.77%
Payout Ratio:22.58% (Trailing 12 Months of Earnings)
26.07% (Based on This Year's Estimates)
28.97% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Dividend History by Quarter for Gilead Sciences (NASDAQ GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/26/2017quarterly$0.522.78%9/14/20179/15/20179/28/2017
5/2/2017quarterly$0.523.09%6/14/20176/16/20176/29/2017
2/7/2017quarterly$0.523.11%3/14/20173/16/20173/30/2017
11/1/2016quarterly$0.472.59%12/13/201612/15/201612/29/2016
7/25/2016quarterly$0.472.32%9/14/20169/16/20169/29/2016
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Gilead Sciences (NASDAQ:GILD)
Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 74.05%
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/21/2017Gregg H AltonEVPSell40,000$74.00$2,960,000.00View SEC Filing  
7/3/2017Gregg H AltonEVPSell5,000$71.06$355,300.00View SEC Filing  
7/3/2017John C MartinInsiderSell73,333$71.00$5,206,643.00View SEC Filing  
5/9/2017John Francis CoganDirectorSell9,943$67.25$668,666.75View SEC Filing  
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.94View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.83View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Gilead Sciences (NASDAQ:GILD)
Latest Headlines for Gilead Sciences (NASDAQ:GILD)
Source:
DateHeadline
finance.yahoo.com logoJ.P. Morgan Elevates Price Targets on Gilead Sciences, Inc. (GILD) and Vertex Pharmaceuticals Incorporated (VRTX) After Glowing 2Q Performance
finance.yahoo.com - July 28 at 5:42 AM
finance.yahoo.com logoGilead Sciences: The Biggest of Beats?
finance.yahoo.com - July 28 at 5:42 AM
americanbankingnews.com logoGilead Sciences, Inc. (NASDAQ:GILD) Given "Outperform" Rating at Cowen and Company
www.americanbankingnews.com - July 28 at 12:56 AM
nasdaq.com logoIs a Surprise Coming for Gilead Sciences (GILD) This Earnings Season? - Nasdaq
www.nasdaq.com - July 28 at 12:39 AM
americanbankingnews.com logoGilead Sciences, Inc. (NASDAQ:GILD) Rating Reiterated by Deutsche Bank AG
www.americanbankingnews.com - July 27 at 10:27 PM
americanbankingnews.com logoBMO Capital Markets Reiterates "Outperform" Rating for Gilead Sciences, Inc. (NASDAQ:GILD)
www.americanbankingnews.com - July 27 at 9:43 PM
nasdaq.com logoGilead Sciences profit falls, but beats Wall Street estimates - Nasdaq
www.nasdaq.com - July 27 at 7:35 PM
investorplace.com logo3 Stocks to Watch on Thursday: Buffalo Wild Wings (BWLD), Gilead Sciences, Inc. (GILD) and PayPal Holdings Inc ... - Investorplace.com
investorplace.com - July 27 at 7:35 PM
investorplace.com logoGilead Sciences, Inc. (GILD) Stock Has Tremendous Potential Even Post-Rally - Investorplace.com
investorplace.com - July 27 at 7:35 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Receives "Hold" Rating from Jefferies Group LLC
www.americanbankingnews.com - July 27 at 7:15 PM
investorplace.com logoGilead Sciences, Inc. (GILD) Stock Has Tremendous Potential Even Post-Rally
investorplace.com - July 27 at 10:15 AM
finance.yahoo.com logoEdited Transcript of GILD earnings conference call or presentation 26-Jul-17 8:30pm GMT
finance.yahoo.com - July 27 at 5:38 AM
marketwatch.com logoGilead Sciences shares rise after quarterly results top Street view - MarketWatch
www.marketwatch.com - July 27 at 12:36 AM
finance.yahoo.com logoGilead beats Street 2Q forecasts
finance.yahoo.com - July 27 at 12:35 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Announces Quarterly Earnings Results
www.americanbankingnews.com - July 26 at 9:14 PM
nasdaq.com logoGilead Sciences Inc. Q2 Profit Falls 19% - Nasdaq
www.nasdaq.com - July 26 at 7:35 PM
benzinga.com logoGilead Sciences, Inc. (NASDAQ:GILD), Verizon Communications Inc ... - Benzinga
www.benzinga.com - July 26 at 7:35 PM
seekingalpha.com logoSell Gilead Regardless Of Q2 Results - Seeking Alpha
seekingalpha.com - July 26 at 7:35 PM
finance.yahoo.com logoGilead (GILD) Shares Pop on Q2 Earnings and Revenue Beats
finance.yahoo.com - July 26 at 7:35 PM
finance.yahoo.com logoGilead Still Doesn't Get a Deal Pass
finance.yahoo.com - July 26 at 7:35 PM
finance.yahoo.com logo"Fast Money" final trades: GILD, UAL and more
finance.yahoo.com - July 26 at 7:35 PM
finance.yahoo.com logoGilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales
finance.yahoo.com - July 26 at 7:35 PM
finance.yahoo.com logoGilead Sciences profit falls, but beats Wall Street estimates
finance.yahoo.com - July 26 at 7:35 PM
americanbankingnews.com logoRedburn Partners Begins Coverage on Gilead Sciences, Inc. (GILD)
www.americanbankingnews.com - July 26 at 6:51 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Declares Quarterly Dividend of $0.52
www.americanbankingnews.com - July 26 at 5:31 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) EVP Gregg H. Alton Sells 40,000 Shares
www.americanbankingnews.com - July 25 at 7:26 PM
seekingalpha.com logoGilead: Q2 Earnings Preview - Seeking Alpha
seekingalpha.com - July 25 at 7:19 PM
finance.yahoo.com logoGilead Sciences, Inc.’s (GILD) Bictegravir Primed for Competition in HIV Market: Cowen
finance.yahoo.com - July 25 at 7:19 PM
finance.yahoo.com logoIs a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?
finance.yahoo.com - July 25 at 7:19 PM
finance.yahoo.com logoDrug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK
finance.yahoo.com - July 25 at 7:19 PM
finance.yahoo.com logoWhat To Look For In Gilead Sciences, Inc. (GILD) Earnings
finance.yahoo.com - July 25 at 7:19 PM
finance.yahoo.com logoBiotech still has more room to run: Technician
finance.yahoo.com - July 25 at 7:19 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Given Outperform Rating at Robert W. Baird
www.americanbankingnews.com - July 25 at 2:44 PM
americanbankingnews.com logoGilead Sciences' (NASDAQ:GILD) "Hold" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - July 25 at 12:12 PM
fool.com logo3 Dividend Stocks That Thrive in Bear Markets
www.fool.com - July 25 at 7:52 AM
streetinsider.com logoGilead Sciences (GILD) Reports Phase 3 Results for Investigational Fixed-Dose ...
www.streetinsider.com - July 25 at 1:46 AM
seekingalpha.com logoRecent Buy: Gilead Sciences
seekingalpha.com - July 25 at 1:46 AM
finance.yahoo.com logoJ.P. Morgan Comments on Gilead Sciences, Inc. (GILD) Following Clinical Results in HIV
finance.yahoo.com - July 25 at 1:46 AM
seekingalpha.com logoI Think Gilead Is Worth More than $86 Per Share - Seeking Alpha
seekingalpha.com - July 24 at 8:44 PM
marketwatch.com logoGilead Sciences says late-stage results for HIV drug combination are similar to standard of care - MarketWatch
www.marketwatch.com - July 24 at 8:44 PM
finance.yahoo.com logoGilead Sciences: There's Always Safety
finance.yahoo.com - July 24 at 8:44 PM
finance.yahoo.com logo3 Things You Can Expect in Gilead Sciences' Q2 Update
finance.yahoo.com - July 24 at 8:44 PM
finance.yahoo.com logoGilead's HIV Drug Matches Glaxo Rival In Late-Stage Trials
finance.yahoo.com - July 24 at 8:44 PM
investorplace.com logoGilead Sciences, Inc. (GILD) Stock Is a 2-for-1 Deal
investorplace.com - July 24 at 12:31 PM
finance.yahoo.com logoGilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
finance.yahoo.com - July 24 at 9:07 AM
finance.yahoo.com logoGilead Sciences says late-stage results for HIV drug combination are similar to standard of care
finance.yahoo.com - July 24 at 9:07 AM
finance.yahoo.com logoThe Worm Has Turned in Biotech's Favor
finance.yahoo.com - July 23 at 6:32 PM
fool.com logoBetter Buy: Celgene Corporation vs. Gilead Sciences, Inc.
www.fool.com - July 22 at 11:55 AM
americanbankingnews.com logoBMO Capital Markets Reaffirms "Hold" Rating for Gilead Sciences, Inc. (NASDAQ:GILD)
www.americanbankingnews.com - July 22 at 11:34 AM
barrons.com logoWill Gilead Beat 2Q Earnings? Perhaps…But Does It Matter? - Barron's
www.barrons.com - July 22 at 12:24 AM

Social

Chart

Gilead Sciences (GILD) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff